Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.

Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR.

Clin Cancer Res. 2009 Oct 1;15(19):6232-40. doi: 10.1158/1078-0432.CCR-09-0224. Epub 2009 Sep 29.

2.

Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.

Kantarjian H, O'Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ.

Cancer. 2008 Oct 1;113(7 Suppl):1933-52. doi: 10.1002/cncr.23655. Review.

3.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A.

J Clin Oncol. 2008 Jul 1;26(19):3204-12. doi: 10.1200/JCO.2007.14.9260. Epub 2008 Jun 9.

4.

Metabolism and disposition of dasatinib after oral administration to humans.

Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A Jr, Blackwood-Chirchir A, Humphreys WG, Iyer RA.

Drug Metab Dispos. 2008 Jul;36(7):1357-64. doi: 10.1124/dmd.107.018267. Epub 2008 Apr 17.

5.

Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?

Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J.

Cancer. 2008 Feb 15;112(4):837-45.

6.

Initial testing of dasatinib by the pediatric preclinical testing program.

Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, Tajbakhsh M, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA.

Pediatr Blood Cancer. 2008 Jun;50(6):1198-206.

PMID:
17914733
7.

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.

Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, Larson RA, Rege-Cambrin G, Radich J, Hochhaus A, Apanovitch AM, Gollerkeri A, Coutre S.

Blood. 2007 Oct 1;110(7):2309-15. Epub 2007 May 11.

8.

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, Hochhaus A, Guilhot F, Saglio G, Apperley J, Ottmann O, Shah N, Erben P, Branford S, Agarwal P, Gollerkeri A, Baccarani M.

Blood. 2007 Apr 15;109(8):3207-13. Epub 2006 Dec 21.

9.

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.

Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, Countouriotis AM, Shah NP.

Blood. 2007 Mar 15;109(6):2303-9. Epub 2006 Nov 30. Erratum in: Blood. 2007 Sep 1;110(5):1438.

10.

Measures of response: RECIST, WHO, and new alternatives.

Jaffe CC.

J Clin Oncol. 2006 Jul 10;24(20):3245-51. Review.

PMID:
16829648
11.

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, Cortes J, O'Brien S, Nicaise C, Bleickardt E, Blackwood-Chirchir MA, Iyer V, Chen TT, Huang F, Decillis AP, Sawyers CL.

N Engl J Med. 2006 Jun 15;354(24):2531-41.

12.

Overriding imatinib resistance with a novel ABL kinase inhibitor.

Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL.

Science. 2004 Jul 16;305(5682):399-401.

Items per page

Supplemental Content

Write to the Help Desk